While millions silently carry infections without knowing it, our world saw nearly two and a half million cases of just three common STIs reported in the United States in 2021 alone.
Key Takeaways
- In 2021, there were an estimated 2,512,391 cases of chlamydia, gonorrhea, and syphilis reported in the United States
- Globally, more than 1 million STIs are acquired every day, mostly asymptomatic
- In the US, chlamydia was the most common notifiable STI with 1,644,427 cases in 2021
- In 2021, US chlamydia rate was 499.3 per 100,000 population
- Gonorrhea incidence rate in US 2021 was 216.4 per 100,000
- Syphilis total rate in US 2021 was 53.7 per 100,000
- Women 15-24 in US have chlamydia rates 4 times higher than older women
- In 2021, US chlamydia rate for Black females was 1,127.6 per 100,000 vs 166.4 for White females
- Gonorrhea rates in US Black males 15-24 were 2,026 per 100,000 in 2021
- Gonorrhea multidrug-resistant strains 3.4% in US 2021
- Chlamydia trachomatis causes 90% of bacterial STIs in young women
- Neisseria gonorrhoeae azithromycin resistance 5.5% in US 2021
- US chlamydia cases decreased 5% from 2020 to 2021 but still high
- Gonorrhea cases rose 28% in US adolescents 15-24 from 2018-2021
- Syphilis cases increased 80% in US 2018-2022
STIs are a global crisis, with millions of new infections occurring silently each year.
Demographic Variations
1Women 15-24 in US have chlamydia rates 4 times higher than older women
Verified2In 2021, US chlamydia rate for Black females was 1,127.6 per 100,000 vs 166.4 for White females
Verified3Gonorrhea rates in US Black males 15-24 were 2,026 per 100,000 in 2021
Verified4MSM accounted for 53% of primary/secondary syphilis cases in US 2021
Directional5US congenital syphilis highest among American Indian/Alaska Native at 291.2 per 100,000 live births 2021
Single source6Globally, adolescent girls aged 15–19 account for 21% of new HIV infections in Eastern and Southern Africa
Verified7In US, genital herpes seroprevalence HSV-2 is 15.7% in non-Hispanic Blacks vs 3.8% in non-Hispanic Whites
Verified8HPV prevalence higher in US Hispanic women at 47.3% vs 41.7% non-Hispanic White
Verified9In Europe 2022, gonorrhoea highest in men 20–24 years at 1,332 cases per 100,000
Directional10UK 2022 gonorrhoea diagnoses 82% in heterosexuals under 25
Single source11Australia chlamydia highest in 15-29 year olds, 70% of cases
Verified12Canada STI rates highest in Indigenous populations, 5 times national average for chlamydia
Verified13In South Africa, women 15-24 have HIV incidence 8 times higher than men same age
Verified14US syphilis rates 8 times higher in Black males than White males 2021
Directional15Globally, 50% of curable STIs in South-East Asia region among 15-24 year olds
Single source16In US, chlamydia positivity highest in 15-19 females at clinics 23.6%
Verified17MSM gonorrhea rates in UK 2022 were 1,040 per 100,000 vs 36 in heterosexual men
Verified18HPV vaccine uptake lower in US low-income groups, leading to higher cervical dysplasia
Verified19In Brazil, HIV prevalence 0.6% overall but 18% among transgender women
Directional20Europe syphilis 2022 highest in MSM at 92% of cases in some countries
Single source21US 2021 gonorrhea in adolescents 15-24 was 48% of total cases
Verified22Global HIV among sex workers averages 30-50% prevalence in many regions
Verified23In India, STI prevalence higher in urban migrants 12.5% vs rural 6%
Verified24Congenital syphilis in US Hispanics 2021 rate 100.8 per 100,000 live births
Directional25Australia syphilis rates 10 times higher in Aboriginal populations
Single source26In 15-24 year old US females, 40% have ever had HPV
Verified27MSM account for 69% of new HIV diagnoses in US 2021
Verified28Black youth 15-24 have syphilis rates 4x White youth in US
Verified29Women living with HIV globally outnumber men in adolescents
Directional30In US clinics, chlamydia rates highest in Black females 15-24 at 25.9%
Single sourceDemographic Variations Interpretation
These statistics expose a harsh reality: our sexual health outcomes are shamefully stratified, not by personal responsibility alone, but by the intersecting vectors of age, race, ethnicity, sexual orientation, and socioeconomic access, revealing a pandemic of inequity hiding in plain sight.
Incidence Rates
1In 2021, US chlamydia rate was 499.3 per 100,000 population
Verified2Gonorrhea incidence rate in US 2021 was 216.4 per 100,000
Verified3Syphilis total rate in US 2021 was 53.7 per 100,000
Verified4Globally, new syphilis infections total 8 million annually in 15-49 age group
Directional5Chlamydia incidence worldwide 129 million new cases per year
Single source6Gonorrhoea new cases globally 82 million yearly
Verified7Trichomoniasis incidence 156 million new cases annually worldwide
Verified8HIV new infections globally dropped to 1.5 million in 2022 from 2.1 million in 2010
Verified9In US MSM, gonorrhea rate was 8,040 per 100,000 in 2021
Directional10US women aged 15-24 account for nearly half of chlamydia cases, rate 3,067 per 100,000
Single source11Congenital syphilis rate in US 2021 was 59.9 per 100,000 live births
Verified12Europe gonorrhea incidence 48% increase in 2022 to 48 cases per 100,000
Verified13UK gonorrhea rate 2022 was 70.0 per 100,000
Verified14Australia chlamydia rate 2022 was 309.4 per 100,000
Directional15Canada chlamydia incidence 2022 was 273 per 100,000
Single source16HSV-2 incidence globally estimated at 23.6 million symptomatic episodes yearly
Verified17US primary/secondary syphilis rate among women 2021 was 25.5 per 100,000
Verified18Global HPV incidence linked to 620,000 cervical cancer cases yearly
Verified19Hepatitis C new infections worldwide 1.5 million per year
Directional20In 2022, UK syphilis diagnoses 8,724, rate 12.5 per 100,000
Single source21Australia's gonorrhea rate 2022 was 112.2 per 100,000
Verified22Canada gonorrhea rate 2022 64 per 100,000
Verified23In US, chlamydia rates highest in 20-24 year olds at 2,512 per 100,000 females
Verified24MSM primary/secondary syphilis rate US 2021 was 3,017 per 100,000
Directional25Global new HIV infections among young women 25% of total in 2022
Single source26Europe chlamydia cases 2022 216,508, stable
Verified27Trichomoniasis rate in US women higher, estimated 3.1 million prevalent cases
Verified28US gonorrhea rates in Black females 15-24 were 2,512 per 100,000 in 2021
Verified29Congenital syphilis in US increased 167% from 2017 to 2021
Directional30In the US, 2021 chlamydia cases among females were 1,065,132
Single source31Gonorrhea cases in US males 2021: 462,634
Verified32Chlamydia accounts for 75% of STI clinic diagnoses in US adolescents
Verified33In US, syphilis rates among Black males 15-24 were 131.6 per 100,000 in 2021
Verified34Global syphilis incidence rate 0.5% in 15-49 year olds
DirectionalIncidence Rates Interpretation
While it’s genuinely encouraging to see global HIV infections declining, the sheer volume of other STIs screaming from these statistics suggests humanity is, on the whole, being profoundly careless with a baffling dedication to ignoring both condoms and common sense.
Prevalence Statistics
1In 2021, there were an estimated 2,512,391 cases of chlamydia, gonorrhea, and syphilis reported in the United States
Verified2Globally, more than 1 million STIs are acquired every day, mostly asymptomatic
Verified3In the US, chlamydia was the most common notifiable STI with 1,644,427 cases in 2021
Verified4Worldwide, 374 million new cases of four curable STIs (chlamydia, gonorrhoea, syphilis, trichomoniasis) occurred in 2020 among adults aged 15–49 years
Directional5In 2021, US gonorrhea cases reached 716,030, the highest number reported since 1991
Single source6Syphilis cases in the US totaled 176,713 in 2021, including 2,457 cases of congenital syphilis
Verified7In Europe, 2022 saw over 70,000 gonorrhoea cases reported, a 48% increase from 2021
Verified8UK reported 49,209 new gonorrhoea diagnoses in 2022, highest since 1918 records began
Verified9In Australia, 2022 chlamydia notifications were 85,825, stable from previous years
Directional10Canada reported 108,786 chlamydia cases in 2022
Single source11In 2020, an estimated 30.1% of new HIV infections globally were among key populations including sex workers
Verified12HPV prevalence among US females aged 14-59 is 42.5% based on NHANES 2013-2014
Verified13Trichomoniasis causes 156 million new cases annually worldwide
Verified14In sub-Saharan Africa, HSV-2 prevalence among adults is 31-48%
Directional15US primary and secondary syphilis rates were 53.7 per 100,000 in 2021
Single source16Globally, 6% of people aged 15-49 have syphilis
Verified17In 2021, congenital syphilis cases in US increased 30% to 2,457
Verified18Europe reported 37,889 syphilis cases in 2022, up 34% from 2021
Verified19Australia's 2022 syphilis notifications were 6,978
Directional20In the US, 2021 saw 11,941 cases of primary and secondary syphilis among MSM
Single source21Global HIV prevalence is 0.7% among adults 15-49 years, totaling 38.4 million people in 2021
Verified22Hepatitis B prevalence globally is 257 million chronic carriers
Verified23In the US, genital herpes prevalence is 11.9% for ages 14-49
Verified24WHO estimates 490 million non-viral STI cases yearly worldwide
Directional25In 2022, UK chlamydia diagnoses were 217,369
Single source26Canada's 2022 gonorrhea cases were 25,475
Verified27In India, estimated 31.5 million STI cases annually
Verified28Brazil reported 236,272 HIV cases cumulatively by 2022
Verified29South Africa has 7.5 million HIV positive people, prevalence 19.5% in adults
DirectionalPrevalence Statistics Interpretation
While these numbers paint a grim picture of a global silent epidemic, it's clear that our collective complacency is being outmatched by the relentless spread of sexually transmitted infections.
Specific STI Data
1Gonorrhea multidrug-resistant strains 3.4% in US 2021
Verified2Chlamydia trachomatis causes 90% of bacterial STIs in young women
Verified3Neisseria gonorrhoeae azithromycin resistance 5.5% in US 2021
Verified4Treponema pallidum causes syphilis, with 7% neurosyphilis in primary/secondary cases
Directional5HIV-1 subtype B dominant in US, 80% of cases
Single source6Human papillomavirus types 16 and 18 cause 70% of cervical cancers
Verified7Herpes simplex virus type 2 responsible for 90% of genital herpes recurrences
Verified8Trichomonas vaginalis infection doubles HIV acquisition risk in women
Verified9Hepatitis B virus chronic infection in 5-10% adults post-acute infection
Directional10Hepatitis C virus genotype 1 prevalent in 60% US cases
Single source11Mycoplasma genitalium detected in 15-20% non-chlamydial NGU cases
Verified12Chlamydia screening positivity 10.5% in US family planning clinics 2021
Verified13Gonorrhea cephalosporin MIC creep to 0.5 ug/mL in 8.6% US isolates 2021
Verified14Syphilis RPR titers >1:32 in 25% primary cases
Directional15HIV viral load >100,000 copies/mL increases transmission 10-fold
Single source16HPV vaccination prevents 90% of HPV-related cancers with 3 doses
Verified17HSV-1 causes 50% of new genital herpes cases in US
Verified18Trichomoniasis metronidazole resistance 4-10% in US
Verified19HBV vaccine efficacy 95% in preventing perinatal transmission
Directional20HCV spontaneous clearance in 25-45% acute cases
Single source21M. genitalium macrolide resistance 40-50% globally
Verified22Chlamydia LGV serovars rare but increasing in MSM
Verified23Gonococcal pharyngeal infections 10-15% asymptomatic in MSM
Verified24Syphilis Jarisch-Herxheimer reaction in 10-20% treated early syphilis
Directional25HIV PrEP reduces acquisition by 99% with high adherence
Single source26HPV 6/11 cause 90% genital warts
Verified27HSV shedding asymptomatic 10-20% days in HSV-2 positive
Verified28Trichomoniasis prevalence 2.1% US females 14-49 NHANES
Verified29HBV HBsAg positivity 3.5% global adults
Directional30HCV RNA positivity 1% US adults NHANES 2011-2014
Single source31M. genitalium 1-6% prevalence general population, higher in STI clinics
VerifiedSpecific STI Data Interpretation
The sobering truth behind these numbers is that our most intimate moments are now a complex battlefield where bacteria and viruses are rapidly outmaneuvering our medical defenses, demanding smarter prevention, sharper diagnostics, and more resilient treatments.
Trends and Interventions
1US chlamydia cases decreased 5% from 2020 to 2021 but still high
Verified2Gonorrhea cases rose 28% in US adolescents 15-24 from 2018-2021
Verified3Syphilis cases increased 80% in US 2018-2022
Verified4Global HIV new infections declined 22% 2010-2021
Directional5HPV vaccination led to 88% drop in vaccine-type HPV in US teen girls 2006-2016
Single source6Condom use prevents 80-95% HIV transmission per act
Verified7PrEP use increased 50% in US 2020-2021
Verified8Europe STI surveillance shows 25% rise in STIs 2021-2022 post-COVID
Verified9UK chlamydia diagnoses fell 20% during COVID lockdowns, rebounded 2022
Directional10Australia Doxy-PEP trials show 65% reduction gonorrhea/chlamydia in MSM
Single source11Global syphilis elimination target 90% reduction by 2030 via WHO strategy
Verified12US congenital syphilis action plan aims 50% reduction by 2025
Verified13HIV treatment as prevention reduced incidence 50% in communities
Verified14HPV vaccine coverage 60% US teens complete series 2021
Directional15Antibiotic resistance in gonorrhea tripled 2000-2020 globally
Single source16Screening programs reduced chlamydia complications 20-30% in young women
Verified17PrEP awareness 80% but uptake 3% among US MSM at risk 2021
Verified18Global 95-95-95 HIV targets met in 25 countries by 2023
Verified19Canada STI rates stable but syphilis up 92% 2018-2022
Directional20Diphtheria PEP reduced bacterial STIs 66% in Australian trial MSM
Single source21US gonorrhea decreased 5% 2020-2021 due to COVID behaviors
Verified22WHO estimates need 10 million more syphilis tests yearly for elimination
Verified23HSV suppressive therapy reduces shedding 50%, transmission 48%
Verified24Trichomoniasis screening not routine but reduces preterm birth risk
Directional25HBV vaccination coverage 85% global infants by 2022
Single source26HCV cure rates 95% with DAAs, eliminated mother-to-child transmission in pilots
VerifiedTrends and Interventions Interpretation
While we celebrate the victories of vaccines and treatments in our fight against STIs, the sobering surge of syphilis and gonorrhea alongside persistent barriers to prevention tools like PrEP reveals a critical and ongoing battle where complacency is not an option.
Sources & References
- Reference 1CDCcdc.govVisit source
- Reference 2WHOwho.intVisit source
- Reference 3ECDCecdc.europa.euVisit source
- Reference 4GOVgov.ukVisit source
- Reference 5HEALTHhealth.gov.auVisit source
- Reference 6HEALTH-INFOBASEhealth-infobase.canada.caVisit source
- Reference 7UNAIDSunaids.orgVisit source
- Reference 8NCBIncbi.nlm.nih.govVisit source
- Reference 9GOVgov.brVisit source
- Reference 10NICDnicd.ac.zaVisit source
- Reference 11TGAtga.gov.auVisit source